NM_020822.3:c.1200+12T>G

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_020822.3(KCNT1):​c.1200+12T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.23 in 1,603,724 control chromosomes in the GnomAD database, including 44,104 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.23 ( 4132 hom., cov: 32)
Exomes 𝑓: 0.23 ( 39972 hom. )

Consequence

KCNT1
NM_020822.3 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:10

Conservation

PhyloP100: -1.95

Publications

7 publications found
Variant links:
Genes affected
KCNT1 (HGNC:18865): (potassium sodium-activated channel subfamily T member 1) Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a sodium-activated potassium channel subunit which is thought to function in ion conductance and developmental signaling pathways. Mutations in this gene cause the early-onset epileptic disorders, malignant migrating partial seizures of infancy and autosomal dominant nocturnal frontal lobe epilepsy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2012]
KCNT1 Gene-Disease associations (from GenCC):
  • childhood-onset epilepsy syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • developmental and epileptic encephalopathy, 14
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • malignant migrating partial seizures of infancy
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, Orphanet
  • autosomal dominant nocturnal frontal lobe epilepsy 5
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
  • autosomal dominant nocturnal frontal lobe epilepsy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.93).
BP6
Variant 9-135765207-T-G is Benign according to our data. Variant chr9-135765207-T-G is described in ClinVar as Benign. ClinVar VariationId is 261361.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.246 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
KCNT1NM_020822.3 linkc.1200+12T>G intron_variant Intron 12 of 30 ENST00000371757.7 NP_065873.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
KCNT1ENST00000371757.7 linkc.1200+12T>G intron_variant Intron 12 of 30 1 NM_020822.3 ENSP00000360822.2

Frequencies

GnomAD3 genomes
AF:
0.229
AC:
34814
AN:
151764
Hom.:
4129
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.248
Gnomad AMI
AF:
0.289
Gnomad AMR
AF:
0.253
Gnomad ASJ
AF:
0.289
Gnomad EAS
AF:
0.0398
Gnomad SAS
AF:
0.169
Gnomad FIN
AF:
0.164
Gnomad MID
AF:
0.330
Gnomad NFE
AF:
0.237
Gnomad OTH
AF:
0.244
GnomAD2 exomes
AF:
0.216
AC:
53898
AN:
250026
AF XY:
0.214
show subpopulations
Gnomad AFR exome
AF:
0.245
Gnomad AMR exome
AF:
0.258
Gnomad ASJ exome
AF:
0.278
Gnomad EAS exome
AF:
0.0401
Gnomad FIN exome
AF:
0.162
Gnomad NFE exome
AF:
0.242
Gnomad OTH exome
AF:
0.250
GnomAD4 exome
AF:
0.230
AC:
333576
AN:
1451842
Hom.:
39972
Cov.:
32
AF XY:
0.228
AC XY:
164498
AN XY:
720344
show subpopulations
African (AFR)
AF:
0.249
AC:
8294
AN:
33314
American (AMR)
AF:
0.258
AC:
11491
AN:
44574
Ashkenazi Jewish (ASJ)
AF:
0.279
AC:
7245
AN:
26010
East Asian (EAS)
AF:
0.0331
AC:
1305
AN:
39442
South Asian (SAS)
AF:
0.170
AC:
14664
AN:
86046
European-Finnish (FIN)
AF:
0.167
AC:
8742
AN:
52416
Middle Eastern (MID)
AF:
0.324
AC:
1860
AN:
5736
European-Non Finnish (NFE)
AF:
0.241
AC:
266110
AN:
1104352
Other (OTH)
AF:
0.231
AC:
13865
AN:
59952
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.486
Heterozygous variant carriers
0
12801
25602
38402
51203
64004
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
9048
18096
27144
36192
45240
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.229
AC:
34837
AN:
151882
Hom.:
4132
Cov.:
32
AF XY:
0.225
AC XY:
16679
AN XY:
74250
show subpopulations
African (AFR)
AF:
0.249
AC:
10290
AN:
41376
American (AMR)
AF:
0.253
AC:
3861
AN:
15268
Ashkenazi Jewish (ASJ)
AF:
0.289
AC:
1003
AN:
3466
East Asian (EAS)
AF:
0.0397
AC:
205
AN:
5160
South Asian (SAS)
AF:
0.169
AC:
813
AN:
4814
European-Finnish (FIN)
AF:
0.164
AC:
1735
AN:
10594
Middle Eastern (MID)
AF:
0.331
AC:
96
AN:
290
European-Non Finnish (NFE)
AF:
0.237
AC:
16064
AN:
67902
Other (OTH)
AF:
0.241
AC:
507
AN:
2102
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1372
2745
4117
5490
6862
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
356
712
1068
1424
1780
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.232
Hom.:
1776
Bravo
AF:
0.237
Asia WGS
AF:
0.121
AC:
421
AN:
3474

ClinVar

Significance: Benign
Submissions summary: Benign:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:6
Dec 30, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jul 15, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 51% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 47. Only high quality variants are reported. -

Developmental and epileptic encephalopathy, 14;C3554306:Autosomal dominant nocturnal frontal lobe epilepsy 5 Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Developmental and epileptic encephalopathy, 14 Benign:1
Aug 19, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Autosomal dominant nocturnal frontal lobe epilepsy 5 Benign:1
Aug 19, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.93
CADD
Benign
1.2
DANN
Benign
0.33
PhyloP100
-2.0
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs58604946; hg19: chr9-138657053; API